Search Result

Isoforms Recommended:	PI3Kδ

Results for "

PI3Kδ

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Apoptosis (8) Cytochrome P450 (1) Drug Isomer (1) G Protein-coupled Receptor Kinase (GRK) (1) Lipase (1) mTOR (6) PI3K (48)
By Research Areas:	Cancer (38) Infection (1) Inflammation/Immunology (11)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-155232

PI3Kδ-IN-16	PI3K Apoptosis	Cancer
PI3Kδ-IN-16 is a potent and selective inhibitor of PI3Kδ. PI3Kδ-IN-16 has a strong anti-proliferative effect on cells, causing cell cycle arrest and inducing apoptosis .

HY-108418

PI3Kδ-IN-15 1 Publications Verification	PI3K	Cancer
PI3Kδ-IN-15 (compound 6b) is a selective PI3Kδ inhibitor with an IC₅₀ of 0.5 nM for p110δ. PI3Kδ-IN-15 inhibits PI3Kδ with >30-fold higher potency than PI3Kγ, PI3Kβ, and PI3Kα .

HY-101921

PI3Kδ-IN-1	PI3K	Inflammation/Immunology
PI3Kδ-IN-1 is a potent, selective, and efficacious PI3Kδ inhibitor with an IC₅₀ of 1.7 nM.

HY-15288

PI3kδ inhibitor 1	PI3K	Cancer
PI3kδ inhibitor 1 is a potent and selective PI3Kδ inhibitor with an IC₅₀ of 3.8 nM.

HY-134472

PI3Kδ-IN-8	PI3K	Cancer
PI3Kδ-IN-8 is a potent, selective and orally active PI3Kδ inhibitor, with an IC₅₀ of 3.3 nM. PI3Kδ-IN-8 shows selectivity for PI3Kδ over PI3Kα, PI3Kβ, and PI3Kγ (IC₅₀=377.2, 241.6, 17.9 nM, respectively). PI3Kδ-IN-8 has anti-tumor activity .

HY-125376

PI3Kδ-IN-3	PI3K	Cancer
PI3Kδ-IN-3 (Compound 11) is a **PI3Kδ inhibitor (IC₅₀*: 9 nM). PI3Kδ-IN-3 inhibits B cell function. PI3Kδ-IN-3 has good pharmacokinetic properties .***

HY-144254

PI3Kδ-IN-10	PI3K Akt Apoptosis	Cancer
PI3Kδ-IN-10 is a highly potent and orally active PI3Kδ inhibitor with IC₅₀ of 2 nM. PI3Kδ-IN-10 robustly suppresses the downstream AKT pathway to induce subsequent apoptosis in hepatocellular carcinoma models .

HY-158147

PI3Kδ-IN-20	PI3K	Cancer
PI3Kδ-IN-20 (compound (S)-36) is a potent inhibitor of PI3Kδ, with the IC₅₀ of 6.4 nM. PI3Kδ-IN-20 has oral bioactivity. PI3Kδ-IN-20 shows significant suppression of cell proliferation and remarkable induction of apoptosis both in vitro and in vivo .

HY-142646

PI3Kδ-IN-9	PI3K	Cancer
PI3Kδ-IN-9 is a selective PI3Kδ inhibitor with an IC₅₀ value of 3.8 nM.

HY-143472

PI3Kδ-IN-11	PI3K Akt Apoptosis	Cancer
PI3Kδ-IN-11 is a highly potent and selective PI3Kδ inhibitor with IC₅₀ value of 27.5 nM. PI3Kδ-IN-11 dose-dependently blocks the activity of *PI3K/Akt* pathway. PI3Kδ-IN-11 can be used for researching B or T cell-related malignancies .

HY-122593

PI3Kδ-IN-5	PI3K	Cancer
PI3Kδ-IN-5 (compound 7n) is a highly potent and selective inhibitor of PI3Kδ with an IC₅₀ of 0.9 nM .

HY-149235

PI3Kδ-IN-12	PI3K	Inflammation/Immunology
PI3Kδ-IN-12 (compound 13) is a PI3Kδ inhibitor (pIC₅₀ = 5.8), with pKi values of 8.0/6.5/6.4/6.7 for PI3Kδ/γ/β/α, respectively. PI3Kδ-IN-12 can be used in the study of chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) .

HY-155833

PI3Kδ-IN-13	PI3K	Infection Inflammation/Immunology Cancer
PI3Kδ-IN-13 (compound 89) is a PI3Kδ inhibitor (IC₅₀=2.6 nM). PI3Kδ-IN-13 can be used in the research of cell proliferation diseases such as cancer, infection, inflammation and autoimmune diseases .

HY-155975

PI3Kδ-IN-14	PI3K	Inflammation/Immunology
PI3Kδ-IN-14 (Compound (S)-29) is a selective PI3Kδ inhibitor (IC₅₀: 0.8 nM, K_d: 84.8 nM). PI3Kδ-IN-14 binds to the ATP-binding site of the kinase domain of PI3Kδ. PI3Kδ-IN-14 has anti-inflammatory activity by inhibiting the PI3K/AKT pathway. PI3Kδ-IN-14 ameliorates acute lung injury (ALI) .

HY-149634

PI3Kδ-IN-17	PI3K	Cancer
PI3Kδ-IN-17 (Compound S5) is a potent inhibitor of *PI3Kδ, with IC₅₀* of 2.82?nM. PI3Kδ-IN-17 shows strong inhibitory activity of proliferation in SU-DHL-6 cells (IC₅₀ = 0.035 μM) .

HY-157128

PI3Kδ-IN-18	PI3K	Inflammation/Immunology
Se15 is a selective inhibitor of **PI3Kδ with an IC₅₀ value less than 0.1nM. Se15 can be used in research on autoimmune .**

HY-158688

PI3Kδ-IN-21	PI3K	Inflammation/Immunology
PI3Kδ-IN-21 (Compound 31) is a selective inhibitor for phosphoinositide 3-kinases δ (PI3Kδ), with an IC₅₀ of 13.6 nM. PI3Kδ-IN-21 inhibits proliferation and differentation of T cells through PI3K/AKT/mTOR signaling pathway. PI3Kδ-IN-21 exhibits good pharmacokinetic characters in rat model, and attenuates the experimental autoimmune encephalomyelitis in myelin oligodendrocyte glycoprotein (MOG)-induced EAE model .

HY-162647

PI3Kδ-IN-22	PI3K	Inflammation/Immunology
PI3Kδ-IN-22 (Compound 26) is a selective inhibitor for PI3Kδ with pK_i of 9.3. PI3Kδ-IN-22 inhibits PI3Kδ-AKT signaling pathway in THP-1 cells, with pIC₅₀ of 9.4. PI3Kδ-IN-22 exhibits good pharmacokinetic characters in rats .

HY-169983

PI3Kδ-IN-23	PI3K	Cancer
PI3Kδ-IN-23 (compound A11) is a potent inhibitor of PI3Kδ, with the IC₅₀ of 0.27 nM. PI3Kδ-IN-23 bounds to PI3Kδ by covalent-bonding interactions with Lys779. PI3Kδ-IN-23 plays an important role in cancer research .

HY-144993

PI3Kδ/γ-IN-1	PI3K	Cancer
PI3Kδ/γ-IN-1 is a potent, selective *PI3K-δ/γ* inhibitor for research of hematological malignancies.

HY-146789

PI3Kδ/γ-IN-2	PI3K	Cancer
PI3Kδ/γ-IN-2 is a potent PI3Kδ and PI3Kγ dual inhibitor with IC₅₀s of 1 nM and 4.3 nM, respectively. PI3Kδ/γ-IN-2 has favorable oral bioavailability. PI3Kδ/γ-IN-2 has potential for battling B-cell malignancies .

HY-150638

PI3Kδ/γ-IN-3	PI3K Apoptosis	Cancer
PI3Kδ/γ-IN-3 (Compound 58) is a potent and orally active PI3Kδ and PI3Kγ dual inhibitor with IC₅₀s of 1 nM and 16 nM, respectively. PI3Kδ/γ-IN-3 induces tumor cell apoptosis and can be used for B-cell malignancies research .

HY-169121

DA-143	mTOR PI3K	Cancer
DA-143 is a selective DNA-PKcs inhibitor (IC₅₀: 2.5 nM), and the IC₅₀s for mTOR, PI3KΔ, and ATM are 280 nM, 106 nM and 6,594 nM respectively. DA-143 blocks phosphorylation of DNA-PKcs substrates. DA-143 sensitizes cancer cells to Doxorubicin (HY-15142) .

HY-147898

PI3K-IN-33	PI3K Apoptosis	Cancer
PI3K-IN-33 (Compound 6e) is a highly selective *PI3K* inhibitor with IC₅₀ values of 11.73, 6.09 and 11.18 μM for PI3K-α、PI3K-β and PI3K-δ , respectively. PI3K-IN-33 arrests cell cycle at G2/M phase and induces apoptosis. PI3K-IN-33 can be used in leukemia research .

HY-147900

PI3K-IN-35	PI3K Apoptosis	Cancer
PI3K-IN-35 (Compound 6l) is a highly selective *PI3K* inhibitor with IC₅₀ values of 13.98, 7.22 and 10.94 μM for PI3K-α、PI3K-β and PI3K-δ, respectively. PI3K-IN-35 arrests cell cycle at G2/M phase and induces apoptosis. PI3K-IN-35 can be used in leukemia research .

HY-147899

PI3K-IN-34	PI3K Apoptosis	Cancer
PI3K-IN-34 (Compound 6g) is a highly selective *PI3K* inhibitor with IC₅₀ values of 11.73, 6.09 and 11.18 μM for PI3K-α、PI3K-β and PI3K-δ , respectively. PI3K-IN-34 arrests cell cycle at G2/M phase and induces apoptosis. PI3K-IN-34 can be used in leukemia research .

HY-11080

PKI-179 1 Publications Verification	PI3K mTOR	Cancer
PKI-179 is a potent and orally active dual *PI3K/mTOR* inhibitor, with IC₅₀s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for *PI3K-α, PI3K-β, PI3K-γ, PI3K-δ* and mTOR, respectively. PKI-179 also exhibits activity over E545K and H1047R, with IC₅₀s of 14 nM and 11 nM, respectively. PKI-179 shows anti-tumor activity in vivo .

HY-11080A

PKI-179 hydrochloride 1 Publications Verification	PI3K mTOR	Cancer
PKI-179 hydrochloride is a potent and orally active dual *PI3K/mTOR* inhibitor, with IC₅₀s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for *PI3K-α, PI3K-β, PI3K-γ, PI3K-δ* and mTOR, respectively. PKI-179 hydrochloride also exhibits activity over E545K and H1047R, with IC₅₀s of 14 nM and 11 nM, respectively. PKI-179 hydrochloride shows anti-tumor activity in vivo .

HY-131910A

*(R)-IHMT-PI3Kδ-372*	PI3K	Inflammation/Immunology
(R)-IHMT-PI3Kδ-372 (R-18) is a potent and selective PI3Kδ inhibitor with an IC₅₀ of 19 nM. (R)-IHMT-PI3Kδ-372 (R-18) can be used in chronic obstructive pulmonary disease (COPD) research .

HY-131910

*IHMT-PI3Kδ-372*	PI3K Cytochrome P450	Inflammation/Immunology
IHMT-PI3Kδ-372 is a potent and selective PI3Kδ inhibitor with an IC₅₀ of 14 nM. IHMT-PI3Kδ-372 shows high selectivity over other class I PI3Ks (56～83 fold) and other protein kinases. IHMT-PI3Kδ-372 can be uesd for chronic obstructive pulmonary disease (COPD) research .

HY-108418A

*(R)-PI3Kδ-IN-15*	Drug Isomer PI3K	Cancer
(R)-PI3Kδ-IN-15 is the R-enantiomer of PI3Kδ-IN-15 (HY-108418) .

HY-109029

Dezapelisib INCB040093	PI3K	Cancer
Dezapelisib (NCB040093) is a potent inhibitor of phosphatidylinositol 3-kinase δ (PI3Kδ). Dezapelisib is a promising research strategy for select R/R B-cell lymphomas .

HY-15280

GSK2292767	PI3K	Inflammation/Immunology
GSK2292767 is a potent and selective inhibitor of PI3Kδ, with a pIC₅₀ of 10.1. GSK2292767 showing greater than 500-fold selective over the other PI3K isoforms. GSK2292767 can be used for the research of respiratory disease .

HY-147792

WNY1613	PI3K Apoptosis	Cancer
WNY1613 is a potent and selective PI3Kδ inhibitor with piperazinone-containing purine scaffold. WNY1613 induces cancer cell apoptosis and inhibits the phosphorylation of PI3K downstream components in NHL cell lines. WNY1613 exhibits anti-NHL activity in vitro and in vivo .

HY-109068

Parsaclisib 1 Publications Verification INCB050465; IBI-376	PI3K	Cancer
Parsaclisib (INCB050465) is a potent, selective and orally active inhibitor of PI3Kδ, with an IC₅₀ of 1 nM at 1 mM ATP. Parsaclisib shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib can be used for the research of relapsed or refractory B-cell malignancies ^[3].

HY-109068A

Parsaclisib hydrochloride 1 Publications Verification INCB050465 hydrochloride; IBI-376 hydrochloride	PI3K	Cancer
Parsaclisib hydrochloride (INCB050465 hydrochloride) is a potent, selective and orally active inhibitor of PI3Kδ, with an IC₅₀ of 1 nM at 1 mM ATP. Parsaclisib hydrochloride shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib hydrochloride can be used for the research of relapsed or refractory B-cell malignancies ^[3].

HY-131345A

(S)-PI3Kα-IN-4	PI3K	Cancer
(S)-PI3Kα-IN-4 is a potent inhibitor of PI3Kα, with an IC₅₀ of 2.3 nM. (S)-PI3Kα-IN-4 shows 38.3-, 4.25-, and 4.93-fold selectivity for PI3Kα over PI3Kβ, PI3Kδ, and PI3Kγ, respectively. (S)-PI3Kα-IN-4 can be used for the research of cancer .

HY-13514

TG 100713 2 Publications Verification	PI3K	Cancer
TG 100713 is an inhibitor of *PI3K, with IC₅₀s of 24, 50, 165, and 215 nM for PI3*Kδ, γ, α and β isoforms respectively .

HY-143403

PI3K-IN-31	PI3K	Cancer
PI3K-IN-31 (Compound 6b) is a potent *PI3K* inhibitor with IC₅₀s of 3.7 nM, 74 nM, 14.6 nM, and 9.9 nM for PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, respectively. PI3K-IN-31 has anticancer effects .

HY-101798

MDVN1003	PI3K	Cancer
MDVN1003 is a Bruton's tyrosine kinase (BTK) and phosphatidylinositol-3-kinase delta (PI3Kδ) dual inhibitor which prevents the activation of B cells and inhibits the phosphorylation of protein kinase B (AKT) and extracellular signal-regulated kinase 1/2 (ERK 1/2). MDVN1003 can be used for non-Hodgkin’s lymphoma (NHL) research .

HY-113572

PX-866-17OH	PI3K	Cancer
PX-866-17OH is the metabolite of PX-866 (Sonolisib, HY-N6775) and a pan-isoform inhibitor of *PI3K* with IC₅₀s of 14, 57, 131, and 148 nM against PI3Kα, PI3Kβ, PI3Kɣ, and PI3Kδ, respectively .

HY-143404

PI3K-IN-30 1 Publications Verification	PI3K	Cancer
PI3K-IN-30 (compound 6d) is a potent *PI3K* inhibitor with IC₅₀s of 5.1, 136, 30.7 and 8.9 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively .

HY-128333

PI3K/mTOR Inhibitor-4	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-4 is an orally active pan-class I *PI3K/mTOR* inhibitor. PI3K/mTOR Inhibitor-4 has enzymatic inhibition activity for PI3Kα, PI3Kγ, PI3Kδ and mTOR with IC₅₀ values of 0.63 nM, 22 nM, 9.2 nM and 13.85 nM, respectively. PI3K/mTOR Inhibitor-4 can be used for the research of cancer .

HY-13440

AMG 511 2 Publications Verification	PI3K	Cancer
AMG 511 is a potent and orally available pan inhibitor of class I *PI3Ks, with K_is of 4 nM, 6 nM, 2 nM and 1 nM for PI3Kα, β, δ and γ, respectively. AMG 511 significantly suppresses PI3*K signaling that is indicated by p-Akt (Ser473) decrease. AMG 511 exhibits anti-tumor activity in mouse glioblastoma xenograft model .

HY-10812

GNE-490	PI3K mTOR	Cancer
GNE-490, a (thienopyrimidin-2-yl)aminopyrimidine, is a potent pan-PI3K inhibitor with IC₅₀s of 3.5 nM, 25 nM, 5.2 nM, 15 nM for PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, respectively. GNE-490 has >200 fold selectivity for mTOR (IC₅₀=750 nM). GNE-490 shows potent suppression efficacy profile against MCF7.1 breast cancer xenograft model .

HY-123849

SN32976	PI3K mTOR	Cancer
SN32976 is a potent and selective class I *PI3K* and mTOR inhibitor with IC₅₀s of 15.1 nM, 461 nM, 110 nM, 134 nM and 194 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ and mTOR, respectively. SN32976 shows high selectivity among other 442 kinases. SN32976 shows anticancer effects .

HY-147419

Vulolisib	PI3K	Cancer
Vulolisib is a potent and orally active phosphatidylinositol 3-kinase (PI3K) inhibitor, with IC₅₀ values of 0.2 nM, 168 nM, 90 nM and 49 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively. Antiproliferative and antineoplastic activity .

HY-123862

LAS195319	PI3K Lipase G Protein-coupled Receptor Kinase (GRK)	Inflammation/Immunology
LAS195319 is an orally active and potent inhibitor against PI3Kδ with an IC₅₀ value of 0.5 nM. LAS195319 is also a highly selective inhibitor against an extensive panel of proteins, lipid kinases and GPCRs. LAS195319 causes an inhibition of neutrophil and eosinophil infiltration. LAS195319 is promising for research of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

PI3Kδ

Inhibitors & Agonists